Single Cell Omics Market size was valued at USD 1.96 billion in 2024 and is anticipated to reach USD 6.34 billion by 2032, at a CAGR of 15.8% during the forecast period.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2023
Base Year
2024
Forecast Period
2025-2032
Single Cell Omics Market Size 2024
USD 1.96 billion
Single Cell Omics Market, CAGR
15.8%
Single Cell Omics Market Size 2032
USD 6.34 billion
The Single Cell Omics market grows rapidly due to rising demand for precision medicine, advancements in sequencing technologies, and increasing applications in diagnostics and drug discovery. It benefits from expanding multi-omics approaches, enabling integrated analysis of genomics, transcriptomics, proteomics, and metabolomics at the single-cell level. Artificial intelligence and advanced bioinformatics improve data interpretation, driving innovation and research efficiency. Growing investments from pharmaceutical companies, academic institutions, and government initiatives support technology adoption.
The Single Cell Omics market shows strong geographical expansion, with North America leading due to advanced research infrastructure and high adoption of innovative technologies. Europe follows with growing investments in genomics and collaborations among research institutions. Asia-Pacific demonstrates the fastest growth, driven by government initiatives, rising healthcare spending, and increasing research activities. Key players shaping the market include Illumina, 10x Genomics, Danaher, and BD, focusing on technological advancements, strategic partnerships, and innovative product development to strengthen their global presence.
Single Cell Omics Market size
Market Insights
The Single Cell Omics market was valued at USD 1.96 billion in 2024 and is expected to reach USD 6.34 billion by 2032, growing at a CAGR of 15.8% during the forecast period.
Rising demand for precision medicine, growing research in genomics, and technological advancements in single-cell sequencing drive the adoption of single-cell omics solutions across healthcare and life sciences.
Increasing integration of artificial intelligence, multi-omics approaches, and automation enhances data accuracy, improves research workflows, and supports innovation in diagnostics and therapeutic development.
The competitive landscape features key players such as Illumina, 10x Genomics, Danaher, BD, CYTENA, and Bio-Rad, focusing on product innovation, strategic collaborations, and expanding their global reach.
High costs of instruments, complex implementation processes, and data standardization challenges act as major restraints, limiting accessibility for smaller laboratories and emerging markets.
North America leads the market due to strong investments in genomics and advanced research facilities, while Europe follows with growing technological adoption, and Asia-Pacific records the fastest growth with increasing government support.
Expanding clinical applications in oncology, neurology, immunology, and personalized medicine combined with rising collaborations between academia, healthcare providers, and industry players continue to drive opportunities for long-term market growth.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
Rising Demand for Precision Medicine and Personalized Therapies
The Single Cell Omics market grows due to the increasing focus on precision medicine and personalized treatments. It enables researchers to analyze individual cell behavior, supporting accurate diagnosis and tailored therapies. Healthcare providers adopt single-cell technologies to identify biomarkers and genetic variations more effectively. Pharmaceutical companies integrate these solutions to improve drug discovery processes and patient-specific interventions. Demand strengthens with the rising prevalence of chronic diseases requiring targeted therapies. Continuous advancements enhance the ability to deliver optimized and effective healthcare solutions.
For instance, 10x Genomics’ Chromium platform has been applied in over 5,000 published studies, with single-cell sequencing throughput exceeding 80,000 cells per run, enabling robust biomarker discovery in oncology research.
Technological Advancements Driving Research Capabilities
Rapid technological innovation supports the expansion of the Single Cell Omics market. It introduces high-throughput platforms, next-generation sequencing, and advanced bioinformatics tools that improve data accuracy and efficiency. Researchers leverage integrated solutions to study molecular heterogeneity at unprecedented resolution. These developments accelerate the identification of disease pathways and therapeutic targets. Collaborative efforts between biotech firms and academic institutions boost innovation in single-cell analytics. Adoption rises due to improved affordability and enhanced scalability of modern omics platforms.
For instance, Illumina’s NovaSeq 6000 system processes up to 20 billion reads per run, providing scalability that allows researchers to analyze more than 1 million single cells in population-scale studies.
Increasing Investments in Genomics and Life Sciences Research
Growing investments from governments, private organizations, and venture capitalists accelerate the growth of the Single Cell Omics market. It benefits from funding initiatives supporting large-scale genomic research programs and single-cell profiling projects. Leading countries establish dedicated research infrastructure to advance precision medicine capabilities. Financial support helps laboratories upgrade analytical tools and expand operational capacity. Rising collaborations between pharmaceutical firms and academic institutions enhance discovery pipelines. These efforts strengthen innovation and improve access to next-generation molecular research technologies.
Growing Applications in Disease Diagnosis and Drug Development
The Single Cell Omics market gains momentum from its expanding role in disease diagnosis and drug development. It provides insights into cellular mechanisms, enabling accurate detection of rare cell populations and early-stage diseases. Biopharmaceutical companies use these solutions to design more effective therapies with reduced failure rates. Clinicians adopt single-cell technologies to improve patient stratification and treatment outcomes. Integration with artificial intelligence and data analytics further enhances diagnostic accuracy. The growing relevance of single-cell approaches supports advancements in healthcare and therapeutic innovation.
Market Trends
Integration of Artificial Intelligence and Advanced Analytics
The Single Cell Omics market benefits from the integration of artificial intelligence and machine learning tools in data analysis. It enables researchers to manage vast datasets, uncover complex cellular patterns, and predict disease mechanisms with greater precision. AI-driven algorithms improve speed and accuracy in interpreting single-cell sequencing results. Pharmaceutical companies adopt these tools to enhance biomarker identification and drug target discovery. Automated workflows streamline processes and reduce human error in experimental analysis. Growing reliance on data-driven platforms supports improved research efficiency and deeper biological insights.
For instance, BGI Genomics launched its single-cell sequencing service in China, processing over 200,000 cells per project to support national precision medicine programs.
Rising Adoption of Multi-Omics Approaches
The Single Cell Omics market experiences significant growth with the increasing use of multi-omics techniques. It allows researchers to analyze genomics, transcriptomics, proteomics, and metabolomics within individual cells simultaneously. This integrated approach strengthens understanding of cellular heterogeneity and disease mechanisms. Leading companies invest in developing multi-omics platforms that deliver comprehensive biological profiling. The demand for combining different omics layers supports advancements in diagnostics and precision medicine. Multi-dimensional insights enable researchers to identify novel therapeutic targets with higher accuracy.
For instance, NVIDIA partnered with Oxford Nanopore to accelerate single-cell analysis, achieving a 10x speed improvement in processing datasets exceeding 50 TB.
Growing Focus on Single-Cell Sequencing Innovations
Technological innovations in sequencing accelerate the expansion of the Single Cell Omics market. It introduces faster, more cost-efficient, and high-throughput platforms for capturing detailed cellular information. Advances in droplet-based and microfluidic technologies enhance scalability and performance. Researchers gain the ability to analyze thousands of cells simultaneously, enabling broader clinical and research applications. Companies invest in next-generation sequencing systems to improve sensitivity and detection of rare cell populations. These innovations reshape biological research and drug development strategies across multiple fields.
Expansion of Clinical Applications and Translational Research
The Single Cell Omics market expands with its growing adoption in clinical diagnostics and translational research. It provides insights into tumor heterogeneity, immune profiling, and treatment response patterns. Hospitals and diagnostic laboratories integrate these technologies to deliver personalized treatment plans. Biopharmaceutical firms leverage single-cell data to accelerate therapeutic development and clinical trial designs. Increased collaboration between research institutions and healthcare providers strengthens application in precision oncology and rare disease studies. The focus on bridging laboratory findings with clinical outcomes drives deeper advancements in patient care.
Market Challenges Analysis
High Costs and Complex Implementation Processes
The Single Cell Omics market faces challenges due to the high costs associated with advanced sequencing technologies and data analysis tools. It requires significant investments in infrastructure, reagents, and computational resources, making adoption difficult for smaller research facilities. Many laboratories struggle to manage the technical complexities of integrating multi-omics platforms into existing workflows. The requirement for specialized equipment and highly trained professionals adds operational burdens. Limited accessibility in developing regions further restricts widespread implementation. These cost and resource constraints slow the pace of market penetration and limit research scalability.
Data Management and Standardization Issues
The Single Cell Omics market also encounters difficulties in handling massive datasets generated from single-cell experiments. It demands advanced bioinformatics capabilities and robust storage solutions to process and interpret complex information effectively. Variability in data quality and lack of standardized protocols create challenges for cross-study comparisons. Researchers face difficulties in reproducing results due to inconsistent analytical methods and varying platform outputs. Limited interoperability between software tools slows collaborative efforts across institutions. These data-related challenges hinder the seamless integration of findings into clinical and translational research applications.
Market Opportunities
Expanding Role in Precision Medicine and Targeted Therapies
The Single Cell Omics market creates strong opportunities through its growing role in precision medicine and targeted therapy development. It enables deeper insights into cellular heterogeneity, allowing researchers to identify disease-specific biomarkers and therapeutic targets. Pharmaceutical companies leverage single-cell technologies to design highly personalized treatments that improve patient outcomes. The ability to study immune responses and tumor microenvironments enhances cancer research and drug discovery. Healthcare providers adopt these solutions to optimize treatment strategies based on patient-specific cellular profiles. Increasing demand for customized therapies strengthens the market’s relevance in next-generation medical advancements.
Rising Collaborations and Technological Advancements
Opportunities in the Single Cell Omics market expand with increasing collaborations between academic institutions, biotechnology firms, and pharmaceutical companies. It benefits from joint efforts aimed at developing innovative platforms that combine high-throughput analysis with advanced bioinformatics capabilities. Emerging technologies such as spatial transcriptomics and integrated multi-omics tools open new research possibilities. Strategic partnerships accelerate commercialization and improve access to cutting-edge solutions globally. Governments and private investors support initiatives that drive faster adoption and innovation in this field. These advancements position single-cell technologies as critical enablers of future breakthroughs in clinical diagnostics and therapeutic development.
Market Segmentation Analysis:
By Product Type:
The Single Cell Omics market is segmented into single-cell genomics, single-cell transcriptomics, single-cell proteomics, and single-cell metabolomics. Single-cell genomics dominates due to its extensive application in studying genetic variations and understanding disease mechanisms at the molecular level. It enables researchers to analyze DNA sequences with greater precision and supports advancements in personalized medicine. Single-cell transcriptomics grows rapidly with its ability to profile RNA expressions, enabling better insights into cellular functions. Single-cell proteomics focuses on studying protein dynamics and signaling pathways, helping researchers uncover complex biological processes. Single-cell metabolomics gains traction in understanding metabolic interactions within individual cells, enhancing disease profiling and drug development efforts.
For instance, Fluidigm’s C1 system enables capture and processing of up to 800 individual cells per chip, supporting high-resolution single-cell transcriptomic profiling.
ByApplication:
The Single Cell Omics market expands across oncology, cell biology, neurology, and immunology applications. Oncology leads the segment due to the rising need for cancer profiling, early detection, and targeted therapies. It enables researchers to identify tumor heterogeneity and track therapy responses at the cellular level. Cell biology benefits from single-cell technologies by advancing research on developmental processes and functional diversity among cells. Neurology adopts these solutions to investigate neurodegenerative diseases and brain cell interactions with greater accuracy. Immunology applications grow as single-cell tools enhance immune profiling and support vaccine development, boosting clinical outcomes.
For instance, NanoString’s CosMx Spatial Molecular Imager measures up to 1,000 RNA and protein targets across 500,000 cells per tissue section, enabling detailed immune profiling in cancer diagnostics.
By End-User:
The Single Cell Omics market serves pharmaceutical and biotechnology companies, academic and research organizations, and hospital and diagnostic laboratories. Pharmaceutical and biotechnology companies dominate the segment by using these technologies for drug discovery, biomarker identification, and therapeutic development. It supports faster clinical trial designs and precision-based treatments. Academic and research organizations contribute significantly by driving innovation and expanding single-cell applications through large-scale studies. Hospital and diagnostic laboratories adopt single-cell technologies to enhance early disease detection, patient stratification, and personalized treatment planning. The growing integration across these end-user categories supports wider adoption and accelerates healthcare transformation.
Segments:
Based on Product Type:
Single-Cell Genomics
Single-Cell Transcriptomics
Single-Cell Proteomics
Single-Cell Metabolomics
Based on Application:
Oncology
Cell biology
Neurology
Immunology
Based on End-User:
Pharmaceutical & Biotechnology Companies
Academic and Research Organizations
Hospital and Diagnostic Laboratories
Based on the Geography:
North America
U.S.
Canada
Mexico
Europe
UK
France
Germany
Italy
Spain
Russia
Belgium
Netherlands
Austria
Sweden
Poland
Denmark
Switzerland
Rest of Europe
Asia Pacific
China
Japan
South Korea
India
Australia
Thailand
Indonesia
Vietnam
Malaysia
Philippines
Taiwan
Rest of Asia Pacific
Latin America
Brazil
Argentina
Peru
Chile
Colombia
Rest of Latin America
Middle East
UAE
KSA
Israel
Turkey
Iran
Rest of Middle East
Africa
Egypt
Nigeria
Algeria
Morocco
Rest of Africa
Regional Analysis
North America
North America dominates the Single Cell Omics market, holding a market share of 38% in 2024. It benefits from strong investments in genomics research, advanced healthcare infrastructure, and widespread adoption of precision medicine technologies. The region witnesses significant funding from both government agencies and private organizations to accelerate single-cell analysis innovations. Pharmaceutical and biotechnology companies based in the U.S. and Canada leverage these technologies for drug discovery and clinical trial optimization. Research institutions collaborate with industry leaders to enhance capabilities in personalized medicine and cancer genomics. Rising demand for advanced diagnostic solutions and early disease detection further strengthens the market position in the region.
Europe
Europe accounts for a market share of 27% in the Single Cell Omics market, supported by growing research funding and strategic collaborations across academic and healthcare institutions. The region benefits from increased adoption of single-cell sequencing in oncology, immunology, and neurological research. Leading countries such as Germany, the U.K., and France invest heavily in technological advancements, driving innovation across multiple application areas. Regulatory support for genomics-based clinical solutions encourages market expansion. Pharmaceutical companies integrate single-cell omics platforms into biomarker discovery and drug development pipelines. Rising investments in multi-omics research infrastructure contribute to strengthening Europe’s competitive position.
Asia-Pacific
The Asia-Pacific region captures a market share of 22% in the Single Cell Omics market and demonstrates the fastest growth rate globally. The region benefits from expanding government initiatives supporting genomics research and the development of advanced healthcare solutions. China, Japan, South Korea, and India lead in adopting single-cell technologies for precision medicine, cancer research, and early disease diagnosis. Increasing investments from both private firms and public organizations accelerate regional technological capabilities. Pharmaceutical companies actively collaborate with academic institutions to develop innovative therapies and diagnostic solutions. The growing presence of local biotechnology firms enhances accessibility and supports broader market penetration.
Latin America
Latin America holds a market share of 7% in the Single Cell Omics market, with Brazil and Mexico emerging as leading contributors. The region sees steady adoption of single-cell sequencing technologies, particularly in oncology and infectious disease research. Growing collaborations between research institutions and healthcare providers strengthen technological awareness. Limited infrastructure and high implementation costs slow rapid expansion, but government-supported healthcare modernization programs encourage adoption. Multinational pharmaceutical companies increase their presence in the region by establishing strategic partnerships to accelerate research initiatives. Rising awareness of personalized medicine continues to create emerging opportunities for regional market growth.
Middle East & Africa
The Middle East & Africa region represents a market share of 6% in the Single Cell Omics market, driven by increasing investments in advanced healthcare infrastructure. The UAE, Saudi Arabia, and South Africa lead adoption efforts with growing interest in genomics-based clinical research. Government funding supports integration of precision medicine into national healthcare programs. Limited accessibility to high-end technologies restricts broader adoption, but improving R&D infrastructure helps bridge the gap. Collaborations with global biotechnology firms enhance technological transfer and strengthen regional research capabilities. Rising healthcare digitization and expanding diagnostic services create new growth avenues across emerging economies in this region.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
Key players: Illumina, 10x Genomics, Danaher, BD, CYTENA, PerkinElmer, ANGLE, Bio‑Rad, Mission Bio. These leading players compete aggressively by focusing on innovation, technological advancements, and expanding their product portfolios. Illumina maintains a strong presence by leveraging its sequencing platforms and investing in advanced single-cell preparation technologies. 10x Genomics dominates the space with its Chromium platform and multi-omics solutions, enabling high-resolution single-cell analysis and strengthening its competitive edge. Danaher focuses on integrating single-cell genomics and proteomics tools across multiple life science applications, expanding its reach among research institutions and biopharmaceutical companies. BD enhances its market position through advanced flow cytometry and multi-omics systems that improve cellular profiling and precision research. CYTENA specializes in single-cell printing technologies, delivering accurate cell isolation and dispensing solutions to support next-generation research workflows. PerkinElmer and ANGLE contribute innovative platforms for diagnostic and molecular analysis, while Bio-Rad and Mission Bio bring expertise in mutation profiling and sample preparation. The market remains moderately consolidated, with the top players accounting for a significant share of global revenue. Competitive strategies focus on product launches, mergers, acquisitions, and strategic collaborations to enhance technological capabilities. Continuous investment in automation, bioinformatics, and integrated workflows enables these companies to strengthen their market presence and address growing demand in advanced single-cell research and clinical applications.
Recent Developments
In January 2025, Illumina launched significant enhancements to the NovaSeq X Series, introducing a single‑flow‑cell system, a software v1.3 upgrade, and new 25B 100‑ and 200‑cycle kits to support multiomic applications, including its Single‑Cell 3′ RNA Prep solution
In February 2024, CYTENA unveiled its 2nd generation UP. SIGHT and the new C. STUDIO platform, offering an integrated single‑cell dispensing and imaging solution with day‑zero clonality verification, high‑throughput capability, and regulatory-grade imaging analytics for cell line development.
In February 2023, BD introduced a new tool for single-cell multi-omics analysis. It allows researchers to conduct high-throughput studies without compromising sample integrity, potentially accelerating the pace of discovery across a variety of fields.
Market Concentration & Characteristics
The Single Cell Omics market demonstrates a moderately concentrated structure, with a few leading players driving innovation, technological advancements, and revenue growth. It is characterized by rapid adoption of advanced sequencing platforms, integration of multi‑omics solutions, and expanding applications in precision medicine, oncology, neurology, and immunology. Leading companies focus on developing high-throughput technologies, improving data analytics, and enhancing automation to strengthen research efficiency. Intense competition drives continuous product innovation and strategic collaborations among biotechnology firms, academic institutions, and healthcare providers. The market benefits from rising investments, strong demand for personalized therapies, and advancements in artificial intelligence-driven data analysis. It exhibits high entry barriers due to complex technologies, significant infrastructure requirements, and strong intellectual property protections. Growing partnerships and mergers among key players accelerate commercialization while expanding global reach. The emphasis on multi-dimensional biological insights, improved scalability, and integration of advanced bioinformatics defines the market’s evolving characteristics and positions it for sustained long-term growth.
Report Coverage
The research report offers an in-depth analysis based on Product Type,Application, End-User and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
The Single Cell Omics market will witness rapid growth driven by increasing demand for precision medicine and personalized therapeutic solutions.
Integration of artificial intelligence and advanced bioinformatics will improve single-cell data processing and accelerate research outcomes.
Multi-omics approaches combining genomics, transcriptomics, proteomics, and metabolomics will dominate future research strategies.
Advancements in spatial transcriptomics and high-throughput sequencing technologies will enhance cellular profiling accuracy.
Pharmaceutical and biotechnology companies will increase investments in single-cell platforms to accelerate drug discovery and clinical trial development.
Rising collaborations between academic institutions, healthcare providers, and industry players will boost innovation and commercialization.
Automation and miniaturization of single-cell workflows will make technologies more accessible and cost-effective for broader research adoption.
Expanding clinical applications in oncology, immunology, and neurology will drive wider integration into diagnostics and treatment planning.
Government initiatives and funding support for genomics and advanced research programs will strengthen global adoption.
Emerging markets in Asia-Pacific and the Middle East will create significant growth opportunities through infrastructure development and technological adoption.
1. Introduction
1.1. Report Description
1.2. Purpose of the Report
1.3. USP & Key Offerings
1.4. Key Benefits for Stakeholders
1.5. Target Audience
1.6. Report Scope
1.7. Regional Scope
2. Scope and Methodology
2.1. Objectives of the Study
2.2. Stakeholders
2.3. Data Sources
2.3.1. Primary Sources
2.3.2. Secondary Sources
2.4. Market Estimation
2.4.1. Bottom-Up Approach
2.4.2. Top-Down Approach
2.5. Forecasting Methodology
3. Executive Summary
4. Introduction
4.1. Overview
4.2. Key Industry Trends
5. Global Single Cell Omics Market
5.1. Market Overview
5.2. Market Performance
5.3. Impact of COVID-19
5.4. Market Forecast
6. Market Breakup by Product Type
6.1. Single-Cell Genomics
6.1.1. Market Trends
6.1.2. Market Forecast
6.1.3. Revenue Share
6.1.4. Revenue Growth Opportunity
6.2. Single-Cell Transcriptomics
6.2.1. Market Trends
6.2.2. Market Forecast
6.2.3. Revenue Share
6.2.4. Revenue Growth Opportunity
6.3. Single-Cell Proteomics
6.3.1. Market Trends
6.3.2. Market Forecast
6.3.3. Revenue Share
6.3.4. Revenue Growth Opportunity
6.4. Single-Cell Metabolomics
6.4.1. Market Trends
6.4.2. Market Forecast
6.4.3. Revenue Share
6.4.4. Revenue Growth Opportunity
7. Market Breakup by Application
7.1. Oncology
7.1.1. Market Trends
7.1.2. Market Forecast
7.1.3. Revenue Share
7.1.4. Revenue Growth Opportunity
7.2. Cell Biology
7.2.1. Market Trends
7.2.2. Market Forecast
7.2.3. Revenue Share
7.2.4. Revenue Growth Opportunity
7.3. Neurology
7.3.1. Market Trends
7.3.2. Market Forecast
7.3.3. Revenue Share
7.3.4. Revenue Growth Opportunity
7.4. Immunology
7.4.1. Market Trends
7.4.2. Market Forecast
7.4.3. Revenue Share
7.4.4. Revenue Growth Opportunity
8. Market Breakup by End-User
8.1. Pharmaceutical & Biotechnology Companies
8.1.1. Market Trends
8.1.2. Market Forecast
8.1.3. Revenue Share
8.1.4. Revenue Growth Opportunity
8.2. Academic and Research Organizations
8.2.1. Market Trends
8.2.2. Market Forecast
8.2.3. Revenue Share
8.2.4. Revenue Growth Opportunity
8.3. Hospital and Diagnostic Laboratories
8.3.1. Market Trends
8.3.2. Market Forecast
8.3.3. Revenue Share
8.3.4. Revenue Growth Opportunity
9. Market Breakup by Region
9.1. North America
9.1.1. United States
9.1.1.1. Market Trends
9.1.1.2. Market Forecast
9.1.2. Canada
9.1.2.1. Market Trends
9.1.2.2. Market Forecast
9.2. Asia-Pacific
9.2.1. China
9.2.2. Japan
9.2.3. India
9.2.4. South Korea
9.2.5. Australia
9.2.6. Indonesia
9.2.7. Others
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. United Kingdom
9.3.4. Italy
9.3.5. Spain
9.3.6. Russia
9.3.7. Others
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Others
9.5. Middle East and Africa
9.5.1. Market Trends
9.5.2. Market Breakup by Country
9.5.3. Market Forecast
10. SWOT Analysis
10.1. Overview
10.2. Strengths
10.3. Weaknesses
10.4. Opportunities
10.5. Threats
11. Value Chain Analysis
12. Porters Five Forces Analysis
12.1. Overview
12.2. Bargaining Power of Buyers
12.3. Bargaining Power of Suppliers
12.4. Degree of Competition
12.5. Threat of New Entrants
12.6. Threat of Substitutes
13. Price Analysis
14. Competitive Landscape
14.1. Market Structure
14.2. Key Players
14.3. Profiles of Key Players
14.3.1. Illumina, Inc.
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. Financials
14.3.1.4. SWOT Analysis
14.3.2. PerkinElmer Inc.
14.3.2.1. Company Overview
14.3.2.2. Product Portfolio
14.3.2.3. Financials
14.3.2.4. SWOT Analysis
14.3.3. Mission Bio
14.3.3.1. Company Overview
14.3.3.2. Product Portfolio
14.3.3.3. Financials
14.3.3.4. SWOT Analysis
14.3.4. BD
14.3.4.1. Company Overview
14.3.4.2. Product Portfolio
14.3.4.3. Financials
14.3.4.4. SWOT Analysis
14.3.5. CYTENA GmbH
14.3.5.1. Company Overview
14.3.5.2. Product Portfolio
14.3.5.3. Financials
14.3.5.4. SWOT Analysis
14.3.6. Bio-Rad Laboratories, Inc.
14.3.6.1. Company Overview
14.3.6.2. Product Portfolio
14.3.6.3. Financials
14.3.6.4. SWOT Analysis
14.3.7. CELLENION
14.3.7.1. Company Overview
14.3.7.2. Product Portfolio
14.3.7.3. Financials
14.3.7.4. SWOT Analysis
14.3.8. Danaher Corporation
14.3.8.1. Company Overview
14.3.8.2. Product Portfolio
14.3.8.3. Financials
14.3.8.4. SWOT Analysis
14.3.9. 10x Genomics
14.3.9.1. Company Overview
14.3.9.2. Product Portfolio
14.3.9.3. Financials
14.3.9.4. SWOT Analysis
14.3.10. ANGLE plc
14.3.10.1. Company Overview
14.3.10.2. Product Portfolio
14.3.10.3. Financials
14.3.10.4. SWOT Analysis
15. Research Methodology
Request Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions
What is the current market size for Single Cell Omics market, and what is its projected size in 2032?
The Single Cell Omics market was valued at USD 1.96 billion in 2024 and is projected to reach USD 6.34 billion by 2032.
At what Compound Annual Growth Rate is the Single Cell Omics Market projected to grow between 2025 and 2032?
The market is expected to grow at a CAGR of 15.8% during the forecast period from 2025 to 2032.
What are the primary factors fueling the growth of the Single Cell Omics market?
The market growth is driven by rising demand for precision medicine, technological advancements, increasing research investments, and expanding clinical applications.
Who are the leading companies in the Single Cell Omics Market?
Key players include Illumina, 10x Genomics, Danaher, BD, CYTENA, PerkinElmer, ANGLE, Bio-Rad, Mission Bio, and CELLENION.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
Single-Phase String Inverter Market size was valued at USD 2.65 billion in 2024 and is anticipated to reach USD 3.57 billion by 2032, at a CAGR of 3.8% during the forecast period.
Single Board Computer SBC Market size was valued at USD 2.62 billion in 2024 and is anticipated to reach USD 4.5 billion by 2032, at a CAGR of 7% during the forecast period.
Single Screw Extruder Market size was valued at USD 1,450 million in 2024 and is anticipated to reach USD 2,510.1 million by 2032, at a CAGR of 7.1% during the forecast period.
Single Phase Residential Voltage Regulator Market size was valued at USD 143.1 million in 2024 and is anticipated to reach USD 253.3 million by 2032, at a CAGR of 7.4% during the forecast period.
Single Cell Oil Market size was valued at USD 65.1 million in 2024 and is anticipated to reach USD 98.4 million by 2032, at a CAGR of 5.3% during the forecast period.
The Single Core Armoured Cable market size was valued at USD 2.45 billion in 2024 and is anticipated to reach USD 3.82 billion by 2032, growing at a CAGR of 5.7% during the forecast period.
The Single Phase Variable Shunt Reactor market size was valued at USD 362.4 million in 2024 and is anticipated to reach USD 622.7 million by 2032, growing at a CAGR of 7% during the forecast period.
The Single Mode Optical Fibre Market size was valued at USD 2.45 billion in 2024 and is anticipated to reach USD 7.92 billion by 2032, at a CAGR of 15.8% during the forecast period.
The Single-Phase Fixed Shunt Reactor Market was valued at USD 1,384.1 million in 2024 and is projected to reach USD 2,007.9 million by 2032, expanding at a CAGR of 4.76% during the forecast period.
Purchase Options
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$4999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$6999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
